
United States · Health startup
Constant Therapy, founded in 2013 and based in Lexington, Massachusetts, is a digital therapeutics company focused on brain rehabilitation.
Funding reportedLast round: Pre-seed
Follow Constant Therapy and see its new rounds in your feed.Start following
Constant Therapy, founded in 2013 and based in Lexington, Massachusetts, is a digital therapeutics company focused on brain rehabilitation.
The company specializes in personalized cognitive, speech, and language therapy through its AI-driven mobile applications. Constant Therapy aims to enhance therapy effectiveness, improve access to care, and reduce costs for individuals recovering from neurological conditions. The company offers a range of digital services, including a mobile app that features over 60,000 exercises across various task categories. This app provides continuous access to therapy and allows users to customize their rehabilitation plans. Additionally, Constant Therapy supports clinicians with tools to create tailored therapy programs and track patient progress. The platform is designed to assist a diverse audience, including stroke survivors, traumatic brain injury patients, and individuals with aphasia or dementia. Constant Therapy collaborates with notable healthcare institutions, enhancing the delivery of evidence-based care.
Funding, as reported
From Constant Therapy's own website: 1 founder.
AdvisersEhsan Dadgar-Kiani
What they build
Known for
brain recovery appbrain injury recoveryhealth carespeech pathologyremote monitoringevidence-based exercisesdigital healthcognitive therapyclinical data analysisenterprisespersonalized therapyneuroplasticityinformation technology & servicesbig datadigital health platformneuroperformance engine
Built with from their website
Google SheetsJiraGoogle WorkspaceApache SupersetWP EngineAmazon AWSPythonWordpressMailchimp MandrillAI
Google MeetAWS CloudMySQLPHPMysql workbenchAmazon Route 53Google Search ConsoleJava
Add your raise, your deck and your story, and put Constant Therapy in front of investors. Or tell us what we have wrong.